News

DTBE TB Emergency Drug Stockpile Now Accepting Requests

The CDC’s Division of Tuberculosis Elimination (DTBE) has activated its TB emergency drug stockpile. Currently available: Isoniazid 300 mg (30-count 
bottles), expiration 5/31/2026, inventory: 1,578 bottles.

Prioritization
• Directly funded programs with <150 cases: up to 50 bottles for first request
• ≥150 cases: up to 100 bottles for first request
• Additional requests: 50 bottles every 90 days

How to Request
1. Upload a signed request letter to GrantSolutions as a grant message
2. Address letter to your DTBE Project Officer and have the PI/PD sign it
3. Email the letter to your Project Officer and Neela Goswami

Requests must Include
• TB case burden (2023 data)
• Program performance (COT % from 2021 NTIP data; priority for ≥85%)
• Contact info and shipping address
• Quantity requested

Reported Tuberculosis in the United States, 2024

• Reported Tuberculosis in the United States, 2024 | TB in the US, 2024 | CDC

The 2024 data from the National Tuberculosis Surveillance System (NTSS) show that the United States has achieved a 56% decrease in TB cases and a 68% decrease in the TB incidence rate since 1989, the year the United States first committed to the goal of eliminating TB, resulting in one of the lowest incidence rates in the world.  

However, case counts and rates increased for a fourth consecutive year in 2024, including a 7.9% increase in case count and a 6.9% increase in rate in 2024 as compared with 2023. Increases were widespread with 39 of 52 jurisdictions reporting increases in TB case counts and rates from 2023 to 2024; five jurisdictions reported case count increases of 50% or more. Recovery from pandemic-related health care disruptions, post-pandemic increases in travel and migration, and outbreaks in several states have all likely contributed to increases in TB in recent years.  

CDC Calendar

• Follow this link to CDC's Calendar of tuberculosis related events.

Tuberculosis (TB) Treatment Guideline Updates

• Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

The new tuberculosis (TB) treatment guidelines recommend a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. For drug-resistant TB, the updated regimens include bedaquiline, pretomanid, and linezolid, with or without moxifloxacin. These recommendations emphasize the use of all-oral, shorter treatment regimens for eligible individuals.

NTCA Isolation Guidelines

• NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary TB in Community Settings
• Duration of Effective Tuberculosis Treatment, not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for Deisolation in Community Settings

Department of Health and Human Services Notices

• 2024 Technical Instructions for Tuberculosis (TB TIs) for Panel Physicians
• 2024 Technical Instructions (TB TIs) for Civil Surgeons

WHO Updates Drug-Resistant TB Treatment Guidelines

• WHO consolidated guidelines on tuberculosis: module 4: treatment and care

The World Health Organization (WHO) has released an update to the Consolidated Guidelines on Tuberculosis (TB) - Module 4: Treatment and Care, with multiple novel 6- to 9-month regimens for multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), which can be considered if there are barriers to use of the BPaLM regimen introduced in the last update.

Key Updates

• New 6-Month Regimen:  An all-oral, 6-month regimen composed of bedaquiline, delamanid, linezolid, levofloxacin and clofazimine (BDLLfxC) for treating MDR/RR-TB, including cases with additional resistance to fluoroquinolones (pre-XDR-TB).
• Modified 9-Month Regimens: Several potential 9-month regimens including bedaquiline, linezolid, moxifloxacin and pyrazinamide (BLMZ) are suggested as options for patients who are ineligible or who lack access to the 6-month regimens.
• New Two 4-month Regimens: A new regimen for the treatment of drug-susceptible tuberculosis (DS-TB), marking a significant advancement in TB care. This update formally includes two 4-month regimens for the treatment of drug-susceptible tuberculosis (DS-TB), marking a pivotal advancement in TB care.

This chapter incorporates recommendations that were made in 2022, based on new evidence that was available to WHO on the following: the use of the bedaquiline, pretomanid,  linezolid and moxifloxacin (BPaLM) regimen for patients with MDR/RR-TB, and the use of 9-month all-oral bedaquiline-containing regimens for patients with MDR/RR-TB. It also includes new recommendations developed in June 2024 based on new evidence from the BEAT Tuberculosis (BEAT-TB) and endTB trials.

Our newsletter is dedicated to the critical mission of tuberculosis (TB) education and prevention. Each newsletter will include event announcements, updates on the latest TB research, and highlights of our region’s collaborative efforts toward TB elimination.

We invite you to be active participants in shaping the content of our newsletter. Simply submit suggested topics or upcoming events you would like to highlight at TB Times Suggestions.